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The gut-brain axis is a bidirectional communication system which allows the central nervous system 
and gastrointestinal tract to interact with, and respond to each other rapidly and effectively. It is 
becoming increasingly clear that a major player in this complex system are gut bacteria. The 
mechanisms of signal transmission from bacteria to brain are complex and not fully elucidated, but 
include neural, endocrine, immune, and metabolic pathways.    It was initially demonstrated in a 
rodent model of depression that the gut microbiota was altered.  This observation has been 
replicated in patients with major depression who show decreased microbial diversity.  Furthermore, 
when rodents receive a microbiota transplant from a depressed patient their behaviour alters, as 
does their tryptophan metabolism and immune status.  Several studies of psychobiotics (bacteria 
with a potential mental health benefit) have been conducted in healthy populations and in patients 
with depression.  While some psychobiotics have shown efficacy in treating depression other 
bacteria have yielded negative findings.  Larger scale well designed studies are required.   EU funded 
guidelines recommend that patients with depression or vulnerability to depression should be 
encouraged to enhance a plant-based diet with a high content of grains /fibres, fermented foods and 










The 1950’s represent a watershed in the history of psychopharmacology. In this decade the first 
antidepressant discovered was the antibiotic isoniazid which was developed in the USA for treating 
tuberculosis. Unexpected side effects of euphoria, psychostimulation, increased appetite, and 
improved sleep were observed and prompted an interest in the medication as a potential 
antidepressant. Subsequent clinical trials confirmed antidepressant efficacy, which was attributed to 
isoniazid’s ability to inhibit monoamine-oxidase (MAO) and, therefore, increase levels of 
monoamines such as noradrenaline, serotonin and dopamine. The ‘monoamine hypothesis of 
depression’ emerged and heralded the development of further antidepressant medications, 
including the tricyclic antidepressants (TCAs) and serotonin-specific reuptake inhibitors (SSRIs), both 
of which act to increase central monoamine levels. However, over the past twenty years, few new or 
novel antidepressants have emerged and the field of psychopharmacology seems to have hit the 
buffers.  
Novel paradigm 
The view that the antimicrobial action of isoniazid might be responsible for, or at least contributing 
to, its antidepressant action has largely been ignored.  However, a new paradigm in neuroscience 
has emerged which challenges the orthodox view of antidepressant action.  The new paradigm is 
referred to as the microbiota-gut-brain axis (MGB) hypothesis which strongly emphasises the 
important role gut microbes play in regulating brain function and stress responses. 
 The gut-brain axis is a bidirectional communication system which allows the central nervous system 
(CNS) and gastrointestinal tract (GIT) to interact with, and respond to, each other rapidly and 
effectively. Thus, gut homeostasis and function have the ability to reciprocally impact emotional 
states and behaviour. It is becoming increasingly clear that a major player in this complex system are 
gut bacteria. Trillions of bacteria reside in our GIT, outnumbering our own human cells and gut 
viruses add an extra layer of complexity. We now appreciate that the immense collective genetic 
material of these gut microbes, comprising the ‘gut microbiome’, has the ability to shape 
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neurodevelopment and impact psychological functioning to a remarkable extent. While brain-gut 
communication has been a subject of investigation for decades an exploration of gut microbes 
as a vector within this context has only recently been addressed. The mechanisms of signal 
transmission are complex and not fully elucidated, but it is clear they include neural, 
endocrine, immune, and metabolic pathways 1-3.  Preclinical studies have implicated the 
vagus nerve as a fundamental route of communication between gut microbes and centrally-
mediated behavioural effects, as illustrated by the elimination of central Lactobacillus 
rhamnosus effects following full truncal vagotomy 4.  Interestingly, it has been demonstrated 
that individuals who  underwent a full truncal vagotomy for treatment of peptic ulcer disease  
have a decreased risk of certain neurological disorders when they enter old age 5. The gut 
microbiota also regulates key central neurotransmitters such as serotonin by altering levels of 
precursors; for example Bifidobacterium infantis has been shown to elevate plasma 
tryptophan levels and thus influence central 5-HT transmission 6.  Tryptophan is the building 
block of 5HT and the human brain has limited storage capacity therefore requiring a 
continual supply from the intestine. Of probable evolutionary significance is the fact many 
bacteria can synthesise and release neurotransmitters.  For example,  Lactobacillus and 
Bifidobacterium species can produce gamma-aminobutyric acid (GABA): Escheridia, 
Bacillus and Saccharomyces spp. can produce noradrenaline: Candida, Streptococcus, 
Escheridia and Enterococcus spp. can produce serotonin: Bacillus can produce dopamine: 
and Lactobacillus can produce acetylcholine 7,8. These microbe-produced neurotransmitters 
can cross the mucosal layer of the intestine, though it is improbable that they directly 
influence brain function.  Even if they enter the blood stream, which is by no means certain, 
they are incapable of crossing the blood brain barrier (BBB), though they might act on brain 
regions where the BBB is less developed such as the hypothalamus.  Their impact on brain 
function is more likely by acting locally on the enteric nervous system.  Short chain fatty 
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acids (SCFAs), which include butyrate, propionate and acetate are  essential metabolic 
products of gut microbial activity and may exert central effects either through G-protein 
coupled receptors, though such receptors are sparsely concentrated in the mammalian brain.  
They may however act as epigenetic modulators through histone deacetylases (HDACs)9. 
Immune signalling from gut to brain mediated by cytokine molecules is another well 
documented route of communication 10. Cytokines produced at the level of the gut can travel 
via the bloodstream to the brain.  Under normal physiological circumstances they do not 
cross the BBB, but increasing evidence indicates a capacity to signal across the BBB and to 
influence brain areas such as the hypothalamus where the BBB is deficient. It is through the 
latter mechanism the cytokines interleukin (IL)-1 and IL-6 activate the core stress system, the 
hypothalamic-pituitary-adrenal axis (HPA), bringing about the release of cortisol.  This is 
regarded as the most potent activating mechanism of the stress system and may be of 
relevance in conditions such as the depression that emerges with interferon therapy for 
hepatitis and melanoma 11.  
Microbiota in depression 
Dinan and his colleagues studied the gut microbiota in a maternal separation model of 
depression in rats 12.   They reported an overactive HPA response in such animals, together 
with an increase in pro-inflammatory cytokines and a decrease in the diversity of gut 
microbes.  In a recent study the faecal microbiota was sequenced in a depression study 13.    
Forty-six patients with depression and 30 healthy controls were recruited. High-throughput 
pyrosequencing showed that, according to the Shannon index, increased faecal bacterial 
alpha-diversity was found in those currently depressed but not in a group who had responded 
to treatment. Bacteroidetes, Proteobacteria, and Actinobacteria were increased, whereas 
Firmicutes was significantly reduced.   Despite the profound inter-individual variability, 
levels of several predominant genera were significantly different between the depressives and 
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controls. Most notably, the depressives had increased levels of Enterobacteriaceae and 
Alistipes but reduced levels of Faecalibacterium. The authors conclude that further studies 
are necessary to elucidate the temporal and causal relationships between gut microbiota and 
depression and to evaluate the suitability of the microbiome as a biomarker.   In our study 
when rats were given a humanised microbiota from depressed patients as opposed to healthy 
controls they developed a depressive phenotype from a behavioural and immune perspective.  
The depressed patients had elevated cortisol output together with decreased faecal microbial 
richness14 
Development of Psychobiotics  
It is notoriously difficult to develop new psychotherapeutics. This is due, in part, to limited 
knowledge about the neurobiological basis for mental illness and the absence of targetable 
biomarkers. Many psychotropic medications, such as lithium for mania and chlorpromazine as the 
first antipsychotic, were discovered serendipitously and coincidentally impact the gut microbiota15. 
The development of ‘psychobiotics’ has followed a more logical and step-wise course. While the 
term ‘probiotic’ refers to a live organism that, when ingested in adequate amounts, exerts a health 
benefit, a ‘psychobiotic’ is one which is specifically beneficial for mental health16. Most microbiome 
research over the last decade has focussed on understanding the mechanisms of MGB interaction 
through in-vitro and animal studies. While ongoing mechanistic studies are needed in the laboratory, 
a major effort is currently underway to progress the exciting preclinical findings to human studies 
and clinical trials with psychobiotics.  Intriguingly, some psychobiotics, at least in animals, produce 
effects even when heat killed, suggesting that molecules on their surface which active the immune 
system are fundamental for their action17.  
The psychobiotic narrative first gained attention in 2004 when a landmark study18 demonstrated 
that the gut microbiome could dramatically influence the development and function of the HPA axis, 
the body’s primary stress response system which culminates in the production of cortisol, and has 
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consistently been shown to be dysfunctional in major depressive disorder (MDD). This Japanese 
research team demonstrated that germ-free (GF) mice (mice born and housed in sterile conditions, 
thus lacking a microbiome) exhibited an exaggerated stress response with greater cortisol release in 
comparison to their control counterparts. Strikingly, the abnormal response was partially reversed 
by colonisation with faeces from the control mice and completely reversed by feeding with a specific 
bacterial strain, Bifidobacterium infantis. However, the reversal only occurred if recolonization took 
place at an early stage, indicating a critical time period for normal, microbiome-dependent HPA-axis 
development. That the gut microbiome could influence the stress response was a seminal discovery 
which generated much speculation about the antidepressant potential of probiotic bacteria such as 
Bifidobacterium. However, it was early days and much remained to be elucidated about the 
mechanisms of MGB interaction. A dysfunctional HPA axis is only one component of the 
multifaceted aetiology of depression and questions remained about whether the microbiome could 
influence other pathways of interest in depression research such as immune regulation and 
serotonin metabolism.   
The next decade saw great efforts undertaken to increase understanding of the relationship 
between the gut microbiome and immune system. It was well-recognised that depression is a pro-
inflammatory state characterised by elevated pro-inflammatory cytokines such as IL-1, IL-6 and TNF-
alpha19, but the source of these elevated inflammatory markers was unknown. It now appears that 
the gut microbiome plays a key role in generating this pro-inflammatory state. Under normal 
homeostatic conditions gut microbes are safely confined to the gut and prevented from extra-
intestinal access by the tightly-adherent gut epithelial barrier. However, gut permeability can be 
increased by various factors, such as chronic stress, a well-established precipitant of depression. The 
resultant ‘leaky gut’ can lead to translocation of gut bacteria, and bacterial components such as 
lipopolysaccharides (LPS), into the bloodstream, thus stimulating the low-grade immune response 
seen in depression20. Such a view is supported by studies that demonstrate the ability of various 
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probiotics to improve gut barrier function21 and normalise the immune disturbance seen in animal 
models of depression22. 
The potential of the gut microbiome as an antidepressant target is further reinforced by evidence 
that it could influence neurotransmitter pathways. In the first instance, gut bacteria can directly 
produce many common human neurotransmitters including gamma-aminobutyric acid (GABA), 
noradrenaline, serotonin, acetylcholine and dopamine23. Serotonin, the most well-studied of 
neurotransmitters in relation to depressive illness, appears to be particularly susceptible to influence 
by the gut microbiome. A key study  revealed that the plasma serotonin levels of GF-mice were 
almost 3 times less than those of conventional mice24. It was subsequently demonstrated that this 
differential serotonin level was secondary to the remarkable ability of gut microbes to directly 
promote the synthesis of serotonin from its amino acid precursor, tryptophan, in intestinal 
enterochromaffin cells. Furthermore, the gut microbiome was also shown to influence 
serotoninergic levels in the hippocampus, an area of the brain which plays an important role in 
stress, anxiety and depression25.  Rats fed a Bifidobacterium infantis show significant elevations in 
blood tryptophan levels and such bacteria have the necessary capability to synthesize tryptophan. 
Another possible mechanism of action of psychobiotic bacteria may lie in their ability to produce 
short-chain-fatty acids (SCFAs) from the fermentation of non-digestible carbohydrates and proteins 
in the colon. The main SCFAs include propionate, acetate and butyrate and these bacterial 
metabolites appear to exert far-reaching effects in the body including a role in immune signalling 
and regulation of plasma lipid levels. Butyrate, in particular, is of major interest given its ability to 
regulate gene transcription and it has been shown to demonstrate an antidepressant effect in 
rodents26.  It is a powerful HDAC inhibitor with the potential for epigenetic modulation27. 
The major challenge in drug development lies in translating what seems promising in the laboratory 
into the clinical setting. The complexity of human disease means that only a very small fraction of 
new therapeutics progress through to the drug development process from preclinical evaluation to 
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successful clinical trials. The challenge of psychobiotic identification and translation is no different. 
Despite promising preclinical findings, results in human studies have been modest. However, the 
evidence base is growing and clinical research on the antidepressant properties of psychobiotics is 
hopeful.  
On the positive side, most probiotic bacteria likely to have psychobiotic activity are generally 
regarded as safe, which means that the costs of toxicology studies are largely eliminated.  However, 
whether or not bacteria can be adequately protected from an intellectual property perspective has 
yet to be fully determined and until this is done, major pharmaceutical companies may be hesitant 
to enter the market.  After all a company may conduct expensive trials only to find that another 
company enters the market soon after with a bacteria having only minor genomic differences. 
Most human studies investigating the potential of probiotics to improve mood have been conducted 
in healthy subjects and results have been variable. A combination of Lactobacillus helveticus and 
Bifidobacterium longum, administered to 66 healthy adults resulted in slight improvements in mood 
28, as did a polybiotic combination of various Actobacillus, Lactobacillus, Bifidobacterium and 
Streptococcus strains29. Lactobacillus casei-Shirota improved mood in healthy adults with low 
baseline mood scores 30 and, although it did not improve mood in patients with chronic fatigue 
syndrome, it did reduce anxiety scores31.   A study of Bifidobacteria longum 1714 used a placebo-
controlled cross-over design and found an impact on perceived stress, a reduction in awaking 
cortisol and changes in EEG activity32.  In a similar study Lactobacillus rhamnosus JB1 was found 
ineffective33. 
Psychobiotic trials have been undertaken in patients with depression. An Iranian team described 
improvements in Beck Depression Inventory (BDI) scores in adults with a diagnosis of MDD following 
8 weeks of consumption of a polybiotic containing Lactobacillus acidophilus, Lactobacillus casei and 
Bifidobacterium bifidum 34. Interestingly, patients also showed significant decreases in serum insulin 
and CRP concentrations along with increased plasma glutathione levels, thus demonstrating a 
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beneficial probiotic effect on metabolic, immune and anti-oxidant parameters alongside the 
antidepressant action. A major limitation of the study was that no information was provided on the 
concomitant use of antidepressant medication and so it was unclear whether the probiotic was 
being used as an adjunctive or sole treatment. Another Lactobacillus/Bifidobacterium polybiotic 
containing alternative species of the genera (Lactobacillus helveticus and Bifidobacterium longum) 
found no benefit in terms of improving mood or moderating inflammatory or other biomarkers in 
patients with depression 35, thereby highlighting the differential antidepressant potential of species 
within the same bacterial genus. A third clinical trial demonstrated an antidepressant effect of 
Bifidobacterium longum NCC3001 consumed over 10 weeks by patients with comorbid irritable 
bowel syndrome (IBS) 36. However, the presence of IBS represented an obvious confounding factor 
and depressive symptoms were merely self-reported on screening questionnaires with no diagnostic 
interview performed to establish a clinical diagnosis of MDD.  Up to 50% of patients with IBS are 
clinically depressed but whether this depression has the same biology as regular MDD has yet to be 
established.  A study conducted in New Zealand explored the impact of Lactobacillus rhamnosus 
HN001 given during pregnancy.  A total of 423 women took part and received either probiotic or 
placebo. The data show a decrease in depressive and anxiety symptoms post-partum in those 
women taking the probiotic.  This finding needs replication but given the high prevalence of post-
partum depression the approach offers a safe and potentially effective strategy for reducing the 
burden of illness. 
A study of bipolar patients was conducted at John Hopkins37. A total of 66 patients discharged 
following a manic episode were recruited. Half received a combination of a Lactobacillus rhamnosus 
and a Bifidobacterium animalis while the other patients received placebo.   Patients remained on 
their regular medication throughout.  The rates of rehospitalisation were 51% in the placebo group 
and 24% in the psychobiotic group.  Those patients who had the greatest inflammatory phenotype 
showed the greatest response.  
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When one takes this human data as a whole, it provides tentative but definite optimism for the 
future of psychobiotics in the treatment of depression, most likely as an adjunctive strategy 
alongside traditional pharmacological and psychological therapies. Most benefit seems to be derived 
by those with low mood and depressive symptoms at baseline, a conclusion confirmed by recent 
meta-analysis 38. Effects in healthy subjects with normal baseline moods appear to be more limited 
although the use of psychobiotics as a preventative strategy for depression in those at higher risk 
must be considered.  
The major requirements going forward are:  
1. Large placebo-controlled trials with a parallel group design. 
2. A determination as to whether single strain psychobiotics or multi-strain probiotics 
(polybiotics) are more effective. 
3. Dose response studies to determine the optimal doses for psychobiotics. 
The challenges are analysed in detail elsewhere39. 
Prebiotics 
Of course, psychobiotics are only one means of altering the microbiome, and perhaps even, the least 
effective. While the term ‘psychobiotics’ originally referred to beneficial live organisms such as 
bacteria, the definition has been expanded in recent years to include ‘prebiotics’. Prebiotics are non-
digestible carbohydrates which are selectively fermented by bacteria in the large intestine, and can 
therefore be used to target beneficial host bacteria by specifically supporting and enhancing their 
growth (Bindels et al., 2015). Prebiotics include substances such as inulin, fructooligosaccharides 
(FOS), galactooligosaccharides (GOS), resistant starch and other soluble dietary fibres (though not all 
dietary fibres are prebiotic, i.e. not all modify selective gut microbiota). Natural sources of prebiotics 
include fruits and vegetables such as asparagus, leek, banana and chicory, as well as grains such as 
oats and wheat, foodstuffs which have become increasingly lacking in Western-style diets. Evidence 
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for the potential of prebiotics to improve psychological health is accumulating. A FOS+GOS 
combination demonstrated significant antidepressant and anti-anxiety effects in mice exposed to 
chronic stress40 and in healthy human volunteers, GOS supplementation for 3 weeks resulted in 
suppression of the cortisol response and an increase in the processing of positive versus negative 
attentional vigilance41.   Clearly prebiotics are important as part of a healthy diet.  However, it 
remains to be demonstrated that an individual with a microbiota of significantly decreased diversity 
will also benefit from prebiotic administration. 
Microbiota transplantation 
Another means of modifying the microbiome is through the use of faecal microbiota transplantation 
(FMT), a process which involves transferring the faecal matter from one individual to another, 
thereby colonising the recipient with the donor’s microbiota. It has been used to explore the 
potential transference of disease phenotypes to healthy animals by microbiome transplantation 
from specific human conditions or from animal models of disease. FMT from patients with MDD to 
microbiota-depleted rats resulted in the recipient rodents developing a depressive phenotype, both 
behaviourally and biochemically14. Similar findings were seen following depression-related FMT to 
GF-mice42. Such studies strongly support an aetiological role for the gut microbiome in depressive 
illness and have garnered interest in the role of FMT as a therapeutic intervention in psychiatric 
disorders.   However, the studies also stress the necessity for adequate psychiatric phenotyping of 
microbiota donors when patients with chronic Clostridium difficile infection are undergoing 
treatment. 
Most evidence for the therapeutic use of FMT in humans has been in the treatment of 
refractory Clostridium difficile infection , but there is also evidence emerging that it may be 
beneficial in functional gastrointestinal disorders such as IBS, and in metabolic syndrome. A recent 
Japanese study observed psychiatric symptoms in 17 patients who underwent FMT for the 
treatment of IBS, functional diarrhoea or functional constipation. Patients, with elevated depression 
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scores at baseline, experienced a significant improvement in mood which correlated with an 
increase in microbiota diversity43. Although this was an open-label, uncontrolled, observational 
study, it does raise the possibility that FMT may be of benefit in depression. There has, to date, been 
only one FMT interventional study in a neuropsychiatric population. Kang et al44 administered oral 
FMT from healthy donors to 18 children diagnosed with autism spectrum disorder (ASD) over a 10-
week period. They reported an increase in overall bacterial diversity and significant improvements in 
both gastrointestinal and autistic behavioural symptoms, which were maintained at assessment 8 
weeks after treatment had ended. The use of FMT for psychiatric illness is in its infancy but is no 
doubt a field which may offer exciting new therapeutic opportunities.  
Mediterranean diet 
The final, and probably most important, method of introducing microbiota change is by targeting the 
diet. There is strong evidence that adherence to a Mediterranean diet, as well as lower intakes of 
food items such as processed meats and trans fats, confer protection against depression. The 
mechanisms by which specific dietary factors promote resilience to depressive illness are not fully 
understood, but it is likely that the gut microbiome plays a significant role. It has been shown that a 
change in diet can dramatically and rapidly alter the microbiome composition and thus, alter levels 
of health-promoting bacteria and beneficial bacterial metabolites such as SCFAs.  However, which 
components of the Mediterranean diet mediate the effects on mood has yet to be established.  
High levels of polyphenols or polyunsaturated fatty acids are obvious candidates.  EU funded 
guidelines recommend that patients with depression or vulnerability to depression should be 
encouraged to enhance a plant-based diet with a high content of grains /fibres, fermented 
foods and fish45. 
Conclusion: 
Antidepressant therapy has come a long way from Isoniazid and the monoamine hypothesis and 
research in the field has stalled in recent years. However, perhaps the journey will ultimately prove 
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to have been a circular, rather than linear, one. That the first antidepressant arose from an antibiotic 
is surely a notable coincidence in the current psychobiotic climate and forces one to reconsider and 
question widely-accepted concepts with fresh eyes. The traditional view of functional 
gastrointestinal disorders such as IBS is that these are anxiety- or stress-driven conditions, allowing 
for the concept of a top-down, brain-gut influence. New insights on the gut microbiome have turned 
these assumptions on their head and it may well be our gut that is driving the rapidly-escalating 
rates of depression and anxiety, perhaps due to major changes in the Western diet in recent decades 
changing microbiota composition. 
Nonetheless, the subject of psychobiotics is still relatively new. Much work needs to be done to 
further delineate MGB interaction mechanisms and establish the extent of influence of this system 
on physiological and psychological processes. At present the literature is dominated by preclinical 
studies but more human studies are needed to improve characterisation of normal and ‘dysbiotic’, 
or unbalanced, microbiota configurations and to investigate patterns related to specific disease 
processes. Solid conclusions from probiotic studies are limited by the significant heterogeneity 
across trials, in particular in relation to the strain of probiotic, dosage levels and duration of 
treatment. Further studies are required to throw light on these variables and optimise psychobiotic 
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Figure 1 illustrates some of the ways in which the microbiota may be altered to impact upon mood.  
Psychobiotics are live biotherapeutics with a mental health benefit.  Prebiotics are indigestible fibres 
metabolised by bacteria. Faecal microbiota transplantation (FMT) is the most radical therapy. 
